讲座速递丨一周讲座预览
讲座预览，请查收！...
讲座时间
讲座地点
讲座主题
主讲人
2017年3月29日 下午 15:30-17:00
存中楼10楼报告厅
纳米反应器的研究
刘健博士，澳大利亚科廷大学
2:00 p.m.,April 6,2017
Round Gallery Hall, Run Run Shaw Building, Zhaohui Campus, Zhejiang University of Technology
Structure-Based Discovery of Eliquis®/Apixaban, a Novel Factor Xa Anticoagulant
Distinguished Prof. Patrick Y. S. Lam
预知详情，请看下文！
1
寿恒讲堂 152讲：刘健博士讲座预告
寿恒讲堂 152讲：刘健博士讲座预告
3月29日（周三） 下午15:30-17:00
存中楼10楼报告厅
存中楼10楼报告厅
报告摘要
本报告对纳米多孔材料的发展、分类以及本研究团队的相关工作进行介绍，模拟人工细胞构筑具有Core-shell， Yolk-shell， Janus等特殊结构的纳米反应器，并对纳米反应器的进一步的发展进行展望，最后对碳基纳米材料在能源存储与转化中的应用进行简要介绍。
本报告对纳米多孔材料的发展、分类以及本研究团队的相关工作进行介绍，模拟人工细胞构筑具有Core-shell， Yolk-shell， Janus等特殊结构的纳米反应器，并对纳米反应器的进一步的发展进行展望，最后对碳基纳米材料在能源存储与转化中的应用进行简要介绍。
主讲人简介
刘健，博士，现任澳大利亚科廷大学化工系高级讲师，国家级青年千人计划。2008年于中国科学院大连化学物理研究所获得理学博士学位，
师从杨启华研究员和李灿院士；
2009至2013年在澳大利亚昆士兰大学从事博士后研究工作，博士后合作导师乔世璋教授和逯高清院士；2013年被澳大利亚科廷大学聘为讲师；2014年晋升为高级讲师。
刘健博士主要致力于纳米多孔材料的设计合成及在能源、催化相关领域的基础应用研究，在催化纳米功能材料的设计合成与应用等方面取得了一系列重要的原创性成果。在包括Nature Mater.,
Nature Commun., NPG Asia Mater., Angew. Chem. Int. Ed., Chem. Sci., Nano Today,
Adv. Funct. Mater., 等国际刊物发表正式论文130余篇（Nature子刊3篇，Angew. Chem.
7篇）。引用超过7300余次，H因子为43。任Wiley旗下杂志“Asia-Pacific
Journal of Chemical Engineering”执行主编，英国皇家化学会（RSC）旗下杂志“RSC
Advances”副主编。曾获得“第 14 届国际催化大会青年科学家奖” （2008），“UQ Foundation
Research Excellence Award”（澳大利亚昆士兰大学基础研究最高奖，2011）等多项奖励。
刘健，博士，现任澳大利亚科廷大学化工系高级讲师，国家级青年千人计划。2008年于中国科学院大连化学物理研究所获得理学博士学位，
师从杨启华研究员和李灿院士；
2009至2013年在澳大利亚昆士兰大学从事博士后研究工作，博士后合作导师乔世璋教授和逯高清院士；2013年被澳大利亚科廷大学聘为讲师；2014年晋升为高级讲师。
刘健博士主要致力于纳米多孔材料的设计合成及在能源、催化相关领域的基础应用研究，在催化纳米功能材料的设计合成与应用等方面取得了一系列重要的原创性成果。在包括Nature Mater.,
Nature Commun., NPG Asia Mater., Angew. Chem. Int. Ed., Chem. Sci., Nano Today,
Adv. Funct. Mater., 等国际刊物发表正式论文130余篇（Nature子刊3篇，Angew. Chem.
7篇）。引用超过7300余次，H因子为43。任Wiley旗下杂志“Asia-Pacific
Journal of Chemical Engineering”执行主编，英国皇家化学会（RSC）旗下杂志“RSC
Advances”副主编。曾获得“第 14 届国际催化大会青年科学家奖” （2008），“UQ Foundation
Research Excellence Award”（澳大利亚昆士兰大学基础研究最高奖，2011）等多项奖励。
2
Distinguished Prof. Patrick Y. S. Lam学术报告预告
Distinguished Prof. Patrick Y. S. Lam学术报告预告
4月6日（下周四） 下午14:30
Round Gallery Hall, Run Run Shaw Building,（邵逸夫科技馆一楼圆廊） Zhaohui Campus, Zhejiang University
of Technology
Round Gallery Hall, Run Run Shaw Building,（邵逸夫科技馆一楼圆廊） Zhaohui Campus, Zhejiang University
of Technology
报告摘要
Thrombosis is the leading cause of death in developed countries. There is a
significant need for novel antithrombotics with an improved safety profile to
replace Warfarin which has been in use for ~60 years and has significant
bleeding issues. Factor Xa is at the junction of the intrinsic and extrinsic
pathways of the coagulation cascade. Preclinical data has demonstrated that
blocking FXa is an effective approach for anticoagulation with improved safety
profile. Utilizing structure-based drug design tools, focused screening, and
ADME-T innovations, we at Bristol-Myers Squibb had discovered a novel class of
potent, selective and orally bioavailable Factor Xa inhibitors culminating inEliquis®/Apixaban.
Eliquis® was recently approved by FDA and named the“Best New
Medicine of 2012” by Med Ad News. Eliquis® is currently a
“block-buster” drug with annual sales of ~$4B. During the optimization process,
we have also discovered the powerfulChan-Lam Coupling reaction
of copper promoted C-X bond cross-coupling via boronic acids, a complementary
reaction to the Nobel prize Suzuki-Miyaura C-C bond Coupling reaction. In
addition, at the molecular recognition frontier, we have pioneered the first
rational use ofhalogen bonding in structure-based drug design.
Thrombosis is the leading cause of death in developed countries. There is a
significant need for novel antithrombotics with an improved safety profile to
replace Warfarin which has been in use for ~60 years and has significant
bleeding issues. Factor Xa is at the junction of the intrinsic and extrinsic
pathways of the coagulation cascade. Preclinical data has demonstrated that
blocking FXa is an effective approach for anticoagulation with improved safety
profile. Utilizing structure-based drug design tools, focused screening, and
ADME-T innovations, we at Bristol-Myers Squibb had discovered a novel class of
potent, selective and orally bioavailable Factor Xa inhibitors culminating inEliquis®/Apixaban.
Eliquis® was recently approved by FDA and named the“Best New
Medicine of 2012” by Med Ad News. Eliquis® is currently a
“block-buster” drug with annual sales of ~$4B. During the optimization process,
we have also discovered the powerfulChan-Lam Coupling reaction
of copper promoted C-X bond cross-coupling via boronic acids, a complementary
reaction to the Nobel prize Suzuki-Miyaura C-C bond Coupling reaction. In
addition, at the molecular recognition frontier, we have pioneered the first
rational use ofhalogen bonding in structure-based drug design.
主讲人简介
Patrick Lam received his Ph.D. from the University of Rochester (Dr. Louis
Friedrich) and was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late
Prof. Don Cram, 1987 Nobel Laureate in chemistry). He is currently a medicinal
chemistry and drug discovery consultant at Lam Drug Discovery Consulting, LLC,
Distinguished Professor of Chemistry at Baruch S. Blumberg Institute and Adjunct
Professor at Drexel University College of Medicine. He recently retired from a
chemistry director position of Bristol-Myers Squibb Co. He joined DuPont in 1984
and moved to BMS in 2001. In recent years, he has been involved with antivirals
(HBV capsid, surface antigen and cccDNA inhibitors, Dengue Fever inhibitors,
HIV-DCSIGN blockers), antithrombotics (FXIa and FXa inhibitors as
anticoagulants; P2Y1 and PAR4 antagonists as antiplatelet agents), PCSK9
antisense oligonucleotide (ASO) therapeutics, prodrugs and carbohydrates. He has
>30 years of drug discovery experience. His expertise is in innovations in
structure-based drug design, ADME-T, focused libraries, molecular recognition
and nucleic acid therapeutics to deliver biopharma clinical candidates with
novel profiles.
Patrick Lam received his Ph.D. from the University of Rochester (Dr. Louis
Friedrich) and was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late
Prof. Don Cram, 1987 Nobel Laureate in chemistry). He is currently a medicinal
chemistry and drug discovery consultant at Lam Drug Discovery Consulting, LLC,
Distinguished Professor of Chemistry at Baruch S. Blumberg Institute and Adjunct
Professor at Drexel University College of Medicine. He recently retired from a
chemistry director position of Bristol-Myers Squibb Co. He joined DuPont in 1984
and moved to BMS in 2001. In recent years, he has been involved with antivirals
(HBV capsid, surface antigen and cccDNA inhibitors, Dengue Fever inhibitors,
HIV-DCSIGN blockers), antithrombotics (FXIa and FXa inhibitors as
anticoagulants; P2Y1 and PAR4 antagonists as antiplatelet agents), PCSK9
antisense oligonucleotide (ASO) therapeutics, prodrugs and carbohydrates. He has
>30 years of drug discovery experience. His expertise is in innovations in
structure-based drug design, ADME-T, focused libraries, molecular recognition
and nucleic acid therapeutics to deliver biopharma clinical candidates with
novel profiles.
「近期精彩回顾」
四海八荒都来看油菜花了，我有一百种方法让你拍得好看！
☀来源：浙工大官网 各学院网站
☀ 执行编辑：刘鹏真
关注 浙江工业大学研究生
微信扫一扫关注公众号
